Preveden Tomislav, Ruzic Maja, Lendak Dajana, Pete Maria, Abenavoli Ludovico, Brkic Snezana
Clinical Centre of Vojvodina, Clinic for Infectious Diseases, Medical Faculty University of Novi Sad, Serbia.
Rev Recent Clin Trials. 2016;11(3):208-12. doi: 10.2174/1574887111666160724185311.
Chronic ethyl alcohol consuming is well known independent negative predictor of unfavorable natural course and therapy outcome of Chronic Hepatitis C (CHC) infection.
The aim of the present study was to clarify the impact of alcohol consumption on fibrosis rate progression in patients with CHC and Sustained Virologic Response (SVR) rates in patients undergoing treatment with pegylated interferon and ribavirin.
This cross sectional retrospective study included 807 CHC patients underwent liver biopsy and hospitalized at Clinical center of Vojvodina, Novi Sad, Serbia. According to the alcohol consumption equal or greater than 50 g/day prior to liver biopsy, patients were divided into two groups. We compared demographic, clinical, virologic and histopathological markers of CHC, as well as response to antiviral therapy.
We find statistically significant difference (p=0.001) in gender, but not in age (p=0.081), estimated duration of the CHC (p=0.470) and hepatitis C genotype (p=0.545) between two groups. Among patients with CHC who consume alcohol ≥50 g/day there were significantly higher incidence of intravenous drug users (p=0.000). Binary logistic regression showed that the only independent predictors of moderate to severe fibrosis (fibrosis ≥2) were age (p=0.000) and alcohol use (p=0.027). There was not statistically significant difference in SVR rate between two groups (p=0.810).
We believe that this good result in treatment outcome was the consequence of proper selection of patients based primarily on regulations of Republic of Serbia on the necessity of abstinence from the use of alcohol and psychoactive substances at least one year before starting antiviral therapy.
长期饮用乙醇是慢性丙型肝炎（CHC）感染不良自然病程和治疗结果的已知独立负面预测因素。
本研究旨在阐明饮酒对CHC患者纤维化率进展的影响以及对接受聚乙二醇干扰素和利巴韦林治疗患者的持续病毒学应答（SVR）率的影响。
这项横断面回顾性研究纳入了807例接受肝活检并在塞尔维亚诺维萨德伏伊伏丁那临床中心住院的CHC患者。根据肝活检前每日饮酒量等于或大于50克，将患者分为两组。我们比较了CHC的人口统计学、临床、病毒学和组织病理学指标，以及抗病毒治疗的反应。
我们发现两组之间在性别上存在统计学显著差异（p = 0.001），但在年龄（p = 0.081）、CHC估计病程（p = 0.470）和丙型肝炎基因型（p = 0.545）方面无差异。在每日饮酒量≥50克的CHC患者中，静脉吸毒者的发生率显著更高（p = 0.000）。二元逻辑回归显示年龄（p = 0.000）和饮酒（p = 0.027）是中度至重度纤维化（纤维化≥2）的唯一独立预测因素。两组之间的SVR率无统计学显著差异（p = 0.810）。
我们认为，这种良好的治疗结果是主要基于塞尔维亚共和国关于在开始抗病毒治疗前至少一年必须戒酒和禁用精神活性物质的规定对患者进行适当选择的结果。
